ClinicalTrials.gg
CompletedNCT06097663Updated Apr 9, 2026Results posted

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

A Phase 2 interventional study of MAS825 and MAS825 Placebo in Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP), sponsored by Novartis Pharmaceuticals. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 123 studies in Coronary Disease with a site in Germany — 9 open to participants now, 13 under way, 1 of them phase 3. Coronary Disease · Germany.

Enrollment
72nd of 84
31 · median 322
Started
2024
with 2 others
Phase 2
11 of 123
none open now
Registered
116th of 123
by date

Among the 123 studies in Coronary Disease with a site in Germany, this one is the 72nd largest by enrollment of the 84 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 in phase 2, and was the 116th registered.

Coronary Disease

1,521 studies on the registry are indexed under Coronary Disease; 167 are open to participants now.

Browse Coronary Disease studies →

Open to participants now

9 of the 123 studies in Coronary Disease with a site in Germany are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 123 studies in Coronary Disease with a site in Germany, or all of them as a file.
02

Study summary

This Phase 2a clinical trial evaluated the effectiveness, safety, and tolerability of increasing dose strengths of an oral daily medication, DFV890, administered for 12 weeks, or a single s.c. dose of MAS825, to reduce key markers of inflammation related to CVD risk, such as IL-6 and IL-18, in approximately 28 people with known coronary heart disease and TET2 or DNMT3A CHIP (variant allele frequency [VAF] ≥2%).

Read the detailed description

This was a multi-center, randomized, placebo-controlled, participant- and investigator-blinded study.

The study consisted of a screening period up to 30 days; a treatment period of approximately 12 weeks with an end of treatment (EOT) visit on Day 85, which is one day after the last dose of DFV890 or placebo; a follow-up period of approximately 1 week; and a standard safety follow-up call approximately 30 days following the last dose. The overall study duration is approximately 21 weeks.

Participants were randomized to one of five treatment sequences. Based on the treatment sequence assignments, participants started on either a combination of MAS825 and placebo, DFV890 and placebo, or placebo and placebo on Day 1, and then, within each DFV890 treatment sequence, participants received up-titrating doses of DFV890 or placebo at the corresponding study visits. None of the treatment sequences included a combination of both active DFV890 and active MAS825.

03

Conditions studied

  • Coronary Heart Disease
  • Clonal Hematopoiesis of Indeterminate Potential (CHIP)

Browse trials for

Keywords

  • coronary heart disease
  • CHIP
  • inflammatory marker reduction
  • NLRP3 inflammasome inhibitor
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged between 18 - 80 years (inclusive) at the start of screening will be included.
  • Participants must have a (BMI) within the range of 18 - 40 kg/m2 at screening. BMI = Body weight (kg) / [Height (m)]2.
  • Documented spontaneous myocardial infarction (MI) (diagnosed according to the universal MI criteria with or without evidence of ST segment elevation) at least 30 days before the start of screening (Thygesen et al 2007).
  • Known presence of CHIP, restricted to driver mutations in TET2 or DNMT3A with a VAF ≥2%, as documented in the participant's medical history.
  • For participants on statin therapy (HMG-CoA reductase inhibitor) as clinically indicated, participants must be on a stable regimen (at least 4 weeks before randomization), with no planned statin dose changes over the course of the trial treatment period. Unplanned statin dose changes during the trial treatment period may occur.

Exclusion criteria

Exclusion Criteria:

  • Patients receiving concomitant medications that are known to be strong or moderate inducers of cytochrome CYP2C9 enzyme and/or strong inducers of , strong inhibitors of CYP2C9 and/or strong or moderate inhibitors of CYP3A and the treatment cannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to Day 1 and for the duration of the study.
  • At screening, pre-malignant clonal cytopenias or clonal cytopenia of unknown significance (CCUS).
  • History of ongoing, chronic, or major recurrent infectious disease, at the discretion of the Investigator, at the start of screening.
  • Patients with suspected or proven state at screening.
  • Use of any biologic drugs targeting the immune system within 26 weeks of Day 1.
  • Multi-vessel coronary artery bypass graft (CABG) surgery within the past 3 years prior to the start of screening.
  • Planned coronary revascularization (percutaneous coronary intervention (PCI) or CABG) or any other major surgical procedure during the study (until End of Study (EOS)).
  • Symptomatic Class IV heart failure ( [NYHA]) at the start of screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1

    On Day 1, participants received the single s.c. dose of MAS825 and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.

    Drug: MAS825 · Drug: DFV890 placebo

  • Experimental
    Treatment Sequence 2

    On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 10mg QD. The dose of DFV890 was uptitrated to 25mg on Day 43 and to 100mg on Day 64.

    Drug: MAS825 Placebo · Drug: DFV890 · Drug: DFV890 placebo

  • Experimental
    Treatment Sequence 3

    On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 22 when participants started receiving DFV890 25mg QD. The dose of DFV890 was uptitrated to 50mg on Day 43 and to 100mg on Day 64.

    Drug: MAS825 Placebo · Drug: DFV890 · Drug: DFV890 placebo

  • Experimental
    Treatment Sequence 4

    On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 10 mg QD. Participants continued receiving DFV890 10 mg QD until Day 22 when the dose of DFV890 was uptitrated to 25mg QD. On Day 43 the dose of DFV890 was uptitrated to 50mg and on Day 64 to 100mg.

    Drug: MAS825 Placebo · Drug: DFV890

  • Placebo comparator
    Treatment Sequence 5

    On Day 1, participants received the single s.c. dose of MAS825 placebo and DFV890 oral placebo QD. Participants continued receiving DFV890 oral placebo QD until Day 84.

    Drug: MAS825 Placebo · Drug: DFV890 placebo

Interventions

  • DrugMAS825

    Active MAS825 single dose

  • DrugMAS825 Placebo

    MAS825 placebo single dose

  • DrugDFV890

    Oral tablet of DFV890 active once daily

  • DrugDFV890 placebo

    Oral tablet of DFV890 placebo once daily

06

What researchers measure

Primary outcomes

  1. Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model

    Serum levels of IL-6 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-6 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-6 analysis was a model with 2 covariates (IL-6 baseline and bodyweight) and 1 random effect.

    Time frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)

  2. Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model

    Serum levels of IL-18 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-18 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-18 was a model with one covariate (IL-18 baseline) and 1 random effect.

    Time frame: Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)

  3. Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model

    Serum level of IL-6 at Week 3 for MAS825. The circulating serum levels of the cytokine IL-6 was measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. Data was analyzed with a a traditional linear regression model including treatment as a fixed categorical effect, a random intercept effect for participant, and the baseline value of the biomarker and baseline body weight as covariates.

    Time frame: Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.

Secondary outcomes

  1. Trough Plasma Concentration (Ctrough) of DFV890 at Steady-state

    Ctrough is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.

    Time frame: After the last dose of each 3-week dosing period: Day 22 pre-dose, Day 43 pre-dose, Day 64 pre-dose, or Day 85, depending on treatment sequence assignment

  2. MAS825 Serum Concentrations

    MAS825 serum concentrations were determined using a validated target-based sandwich ELISA.

    Time frame: Day 22, Day 43, Day 64 and Day 85

07

Results

Posted Mar 27, 2026

Participant flow

Participants were randomized in a 4:4:4:1:1 ratio to one of the five treatment sequences.

Participant flow — Overall Study
MilestoneTreatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5
Started118822
Pd analysis set118822
Safety analysis set118822
Pk analysis set117720
Completed117521
Not completed01301
Withdrew: Adverse event01200
Withdrew: Subject decision00101

Outcome measures

PrimaryRatio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model

Serum levels of IL-6 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-6 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-6 analysis was a model with 2 covariates (IL-6 baseline and bodyweight) and 1 random effect.

Time frame:
Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Reported as:
Geometric mean · ratio serum levels of IL-6
Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model
ratio serum levels of IL-6DFV890 10 mgDFV890 25 mgDFV890 50 mgDFV890 100 mgPlacebo
Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model0.8602 (0.7117 to 1.0397)0.7558 (0.6615 to 0.8637)0.7002 (0.6146 to 0.7976)0.6657 (0.5495 to 0.8064)1.1219 (0.9594 to 1.3120)
Statistical analysis
  • DFV890 10 mg vs Placebo · Emax model · p = 0.0817 · Ratio of the geometric mean: 0.7667 · 80% CI 0.6012 to 0.9778Ratio of Test (DFV890) versus Reference (placebo)
  • DFV890 25 mg vs Placebo · Emax model · p = 0.008 · Ratio of the geometric mean: 0.6737 · 80% CI 0.5528 to 0.8210Ratio of Test (DFV890) versus Reference (placebo)
  • DFV890 50 mg vs Placebo · Emax model · p = 0.0009 · Ratio of the geometric mean: 0.6241 · 80% CI 0.5257 to 0.7409Ratio of Test (DFV890) versus Reference (placebo)
  • DFV890 100 mg vs Placebo · Emax model · p = 0.0014 · Ratio of the geometric mean: 0.5933 · 80% CI 0.4854 to 0.7251Ratio of Test (DFV890) versus Reference (placebo)
PrimaryRatio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model

Serum levels of IL-18 at 3 weeks after the start of a dosing period for DFV890. The circulating serum levels of the cytokine IL-18 were measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. The Emax model selected for IL-18 was a model with one covariate (IL-18 baseline) and 1 random effect.

Time frame:
Baseline (before first dose of study drug), 3 weeks after the start of a dosing period for DFV890 (between Day 22 and Day 85, depending on treatment sequence assignment)
Reported as:
Geometric mean · ratio serum levels of IL-18
Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model
ratio serum levels of IL-18DFV890 10 mgDFV890 25 mgDFV890 50 mgDFV890 100 mgPlacebo
Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model0.9088 (0.8825 to 0.9358)0.9087 (0.8825 to 0.9357)0.9087 (0.8825 to 0.9357)0.9087 (0.8825 to 0.9357)0.9767 (0.9427 to 1.0119)
Statistical analysis
  • DFV890 10 mg vs Placebo · Emax model · p = 0.007 · Ratio of the geometric mean: 0.9305 · 80% CI 0.8982 to 0.9638Ratio of Test (DFV890) versus Reference (placebo)
  • DFV890 25 mg vs Placebo · Emax model · p = 0.007 · Ratio of the geometric mean: 0.9304 · 80% CI 0.8982 to 0.9638Ratio of Test (DFV890) versus Reference (placebo)
  • DFV890 50 mg vs Placebo · Emax model · p = 0.007 · Ratio of the geometric mean: 0.9304 · 80% CI 0.8982 to 0.9638Ratio of Test (DFV890) versus Reference (placebo)
  • DFV890 100 mg vs Placebo · Emax model · p = 0.007 · Ratio of the geometric mean: 0.9304 · 80% CI 0.8982 to 0.9638Ratio of Test (DFV890) versus Reference (placebo)
PrimaryRatio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model

Serum level of IL-6 at Week 3 for MAS825. The circulating serum levels of the cytokine IL-6 was measured by a validated enzyme-linked immunosorbent assay (ELISA) assay at a qualified vendor. Data was analyzed with a a traditional linear regression model including treatment as a fixed categorical effect, a random intercept effect for participant, and the baseline value of the biomarker and baseline body weight as covariates.

Time frame:
Baseline (before first dose of study drug), 3 weeks after a single MAS825 dose on Day 1.
Reported as:
Geometric mean · ratio serum levels if IL-6
Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model
ratio serum levels if IL-6MAS825Placebo
Ratio to Baseline Serum Levels of IL-6 for MAS825 Based on a Traditional Linear Regression Model0.5406 (0.4287 to 0.6818)1.1335 (0.9488 to 1.3541)
Statistical analysis
  • MAS825 vs Placebo · Regression, Linear · p = 0.0008 · Ratio of the geometric mean: 0.4770 · 80% CI 0.3561 to 0.6388Ratio of Test (MAS825) versus Reference (placebo)
SecondaryTrough Plasma Concentration (Ctrough) of DFV890 at Steady-state

Ctrough is the observed plasma concentration that is just prior to the beginning of, or at the end of a dosing interval.

Time frame:
After the last dose of each 3-week dosing period: Day 22 pre-dose, Day 43 pre-dose, Day 64 pre-dose, or Day 85, depending on treatment sequence assignment
Reported as:
Mean · ng/mL
Trough Plasma Concentration (Ctrough) of DFV890 at Steady-state
ng/mLDFV890 10 mgDFV890 25 mgDFV890 50 mgDFV890 100 mg
Trough Plasma Concentration (Ctrough) of DFV890 at Steady-state144 ± 72.7427 ± 3631200 ± 9142730 ± 3930
SecondaryMAS825 Serum Concentrations

MAS825 serum concentrations were determined using a validated target-based sandwich ELISA.

Time frame:
Day 22, Day 43, Day 64 and Day 85
Reported as:
Mean · ng/mL
MAS825 Serum Concentrations
ng/mLTreatment Sequence 1
Day 2235750.0 ± 8360.62
Day 4322285.7 ± 9080.64
Day 6410574.0 ± 4346.20
EOT (Day 85)7790.0 ± 4403.56

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 114 Days. The DFV890 and placebo dosing periods are 3-week periods but the MAS825 group encompass a 12-week period.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DFV890 10 mg0/10 (0%)0/10 (0%)1/10 (10%)
DFV890 25 mg0/16 (0%)0/16 (0%)6/16 (37.5%)
DFV890 50 mg0/9 (0%)0/9 (0%)2/9 (22.2%)
DFV890 100 mg0/16 (0%)0/16 (0%)3/16 (18.8%)
MAS8250/11 (0%)0/11 (0%)7/11 (63.6%)
Placebo Sessions0/22 (0%)0/22 (0%)9/22 (40.9%)
Placebo Participants0/18 (0%)0/18 (0%)8/18 (44.4%)
DFV890 100 mg Follow-up0/16 (0%)0/16 (0%)3/16 (18.8%)
MAS825 Follow-up0/11 (0%)0/11 (0%)1/11 (9.1%)
Placebo Follow-up0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventDFV890 10 mgDFV890 25 mgDFV890 50 mgDFV890 100 mgMAS825Placebo SessionsPlacebo ParticipantsDFV890 100 mg Follow-upMAS825 Follow-upPlacebo Follow-up
NasopharyngitisInfections and infestations0/100/160/90/162/112/222/180/160/110/2
HeadacheNervous system disorders0/100/160/90/162/110/220/180/160/110/2
Bacterial infectionInfections and infestations0/100/161/90/160/110/220/180/160/110/2
ArthralgiaMusculoskeletal and connective tissue disorders0/101/160/90/160/112/222/180/160/110/2
MyalgiaMusculoskeletal and connective tissue disorders0/100/161/90/160/110/220/180/160/110/2
OsteoarthritisMusculoskeletal and connective tissue disorders0/100/161/90/160/110/220/180/160/110/2
Amylase increasedInvestigations1/100/160/90/160/110/220/180/160/110/2
Lipase increasedInvestigations1/100/160/90/160/110/220/180/160/110/2
DiarrhoeaGastrointestinal disorders0/101/160/90/161/111/221/180/160/110/2
EnteritisGastrointestinal disorders0/100/160/90/160/110/220/180/161/110/2

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Total
<=18 years000000
Between 18 and 65 years313018
>=65 years8752123
Age, Continuous
Age, Continuous(years)Treatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Total
Mean68.9 ± 6.4470.3 ± 5.9270.3 ± 7.2776.0 ± 5.6665.5 ± 6.3669.8 ± 6.40
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Total
Female123107
Male10651224
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment Sequence 1Treatment Sequence 2Treatment Sequence 3Treatment Sequence 4Treatment Sequence 5Total
Black or African American011002
White11772229
08

Study locations

6 sites
  • Washington University
    St Louis, Missouri 63110, United States
  • Vanderbilt University Medical Cent
    Nashville, Tennessee 37232-8805, United States
  • Novartis Investigative Site
    Montreal, Quebec H1T 1C8, Canada
  • Novartis Investigative Site
    Frankfurt am Main, Hesse 60590, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    München, 80636, Germany
09

References and documents

Publications

  • Sumida K, Obeng EA, Kovesdy CP. Clonal Hematopoiesis in Kidney Disease. Clin J Am Soc Nephrol. 2026 Apr 1;21(4):719-721. doi: 10.2215/CJN.0000000895. Epub 2025 Sep 11. No abstract available. PubMed 40932796 ↗
  • Avolio E, Bassani B, Campanile M, Mohammed KA, Muti P, Bruno A, Spinetti G, Madeddu P. Shared molecular, cellular, and environmental hallmarks in cardiovascular disease and cancer: Any place for drug repurposing? Pharmacol Rev. 2025 Mar;77(2):100033. doi: 10.1016/j.pharmr.2024.100033. Epub 2024 Dec 24. PubMed 40148035 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Oct 2024, 8 months.

Results were first posted in Mar 2026, 1 year 5 months after primary completion.

Of 19 phase 2 interventional studies under Coronary Disease, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2023
First posted
Oct 24, 2023
StartActual
Feb 15, 2024
Primary completionActual
Oct 27, 2024
CompletionActual
Nov 4, 2024
Results first posted
Mar 27, 2026
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06097663
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Feb 15, 2024
Primary completion
Oct 27, 2024
Completion
Nov 4, 2024
Results posted
Mar 27, 2026
Last update
Apr 9, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Arumakimig · NLRP3 Inhibitor DFV890

Start the discussion